Search: NPPA
1story
October 2026
-
LicencesGovernment approves cap on margins of non-scheduled anti-cancer drugs at 30% of MRP; NPPA to notify after DGHS expert committee finalises the list
Margin cap: 30% of MRPReliefThe Government has approved a cap on the margins charged in the supply and sale of non-scheduled anti-cancer drugs, limiting them to 30% of the Maximum Retail Price, according to a Department of Pharmaceuticals release of 8 October 2026. An expert committee under the Directorate General of Health Services will finalise the list of medicines, after which NPPA will take a decision and issue the notification. Manufacturers of these drugs will be required to maintain their current production levels.
The morning brief
One email each working morning with the day’s tax, GST and company-law news. It is starting soon; leave your address and it comes to you from day one.